Today, our team will participate in a fireside chat at the Cantor Fitzgerald Global #Healthcare Conference where they’ll discuss the latest developments across our exciting pipeline of degrader medicines. Listen to the live webcast here: https://bit.ly/3MsclLb #CantorHCC
Kymera Therapeutics
生物技术研究
Watertown，MA 30,052 位关注者
Inventing a new class of medicines using Targeted Protein Degradation
关于我们
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on delivering oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Kymera is also progressing degrader oncology programs that target undrugged or poorly drugged proteins to create new ways to fight cancer. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years.
- 网站
-
https://www.kymeratx.com
Kymera Therapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Watertown，MA
- 类型
- 上市公司
- 创立
- 2016
地点
-
主要
获取路线
500 North Beacon Street
4th Floor
US，MA，Watertown，02472
Kymera Therapeutics员工
动态
-
Today, Dapeng Chen will present at the International Society for the Study of Xenobiotics and JSSX meeting showcasing how we’re pushing the field forward with our predictive modeling capabilities that reflect our deep knowledge and understanding of the interplay between targets and drug properties. #ISSX2024 #ReinventingMedicine?#Pioneer
-
-
Today we recognize #AtopicEczemaDay and hope to increase awareness and understanding for this chronic, inflammatory condition and the challenges faced by patients living with this disease. And at Kymera, we’re driven to revolutionize the treatment of immuno-inflammatory diseases by building an industry leading pipeline of oral medicines. #RevolutionizingImmunology #AtopicEczemaUnfiltered?
-
-
This week, our team celebrated #HispanicHeritageMonth with a fun social hour and learned about the history of Hispanic dance styles - including an amazing demo and lesson with Kymerian Alexia Pico, PMP from our Quality team! #Belong
-
-
Great article in Healio today featuring our CMO, Jared Gollob! He discusses our recent #publication in the Journal of Investigative Dermatology highlighting the central role of #IRAK4 signaling in inflammation in HS patients and the transformative potential of KT-474, our first-in-class IRAK4 degrader: https://bit.ly/47n3mVa #RevolutionizingImmunology?
-
-
Don’t miss our CMO Jared Gollob's presentation at the H.C. Wainwright & Co., LLC Global Investment Conference this morning, where he’ll discuss how we’re leveraging our deep scientific expertise to develop next-generation oral small molecule degrader medicines in #immunology. Live webcast here: https://bit.ly/3XrQIkd #RevolutionizingImmunology
-
-
Today we’ll discuss our innovation in the #TPD space, including what’s ahead for Kymera, at the Morgan Stanley Annual Global #Healthcare Conference. Listen to the live webcast of our fireside chat here: https://bit.ly/4g78MHP
-
-
This afternoon, join our team for a fireside chat at the Wells Fargo Annual #Healthcare Conference where they will discuss our recent progress and upcoming milestones. Live webcast available here: https://bit.ly/3Mydp01
-
-
Today, Bin Yang is presenting at the EFMC - European Federation for Medicinal Chemistry and Chemical Biology International Symposium on Medicinal #Chemistry highlighting our leadership and innovation in the #TPD field with the discovery of KT-333, our first-in-class #STAT3 degrader. #EFMCISMC2024 #ReinventingMedicine
-
-
Explore our upcoming investor events in September in our latest press release: https://bit.ly/3AIYmOr
-